摘要
白癜风是一种临床常见的获得性色素脱失性皮肤疾病,全球发病率为0.1%~3%。目前白癜风诊断容易,治疗方法多样,但治愈率低、复发率较高,临床疗效欠佳。近年来随着对白癜风发病机制的深入研究,许多新兴疗法逐渐应用于临床,并取得显著疗效。窄谱中波紫外线(narrow-band ultraviolet-B,NB-UVB)是白癜风经典有效的治疗方法,联合其他疗法能够提高白癜风的复色效果和减少不良反应的发生。该文就NB-UVB与Janus kinase(JAK)激酶抑制剂、α-黑素细胞刺激素类似物(α-melanocyte stimulating hormone,α-MSH)、富血小板血浆(platelet-rich plasma,PRP)和前列腺素联合治疗白癜风的最新研究进行综述。
Vitiligo is a common clinically acquired depigmented skin disease with a global incidence of approximately 0.1%to 3%.At present,the diagnosis of vitiligo is easy and the treatment methods are diverse,but the cure rate is low,the recurrence rate is high,and the clinical efficacy is poor.In recent years,with the in-depth study of the pathogenesis of vitiligo,many emerging therapies have been gradually applied in clinical practice and achieved significant results.Narrowband ultraviolet B is a classic and effective treatment for vitiligo,combined with other therapies can improve the repigmentation effect of vitiligo and reduce the occurrence of adverse reactions.This article reviews the latest research on the combination of NB-UVB with JAK kinase inhibitors,α-melanocyte stimulating hormone analogues,platelet-rich plasma and prostaglandins,in the treatment of vitiligo.
作者
石静艺
王红娟
康晓静
SHI Jing-yi;WANG Hong-juan;KANG Xiao-jing(Xinjiang Medical University,Urumqi 830001,China)
出处
《实用皮肤病学杂志》
2023年第3期164-167,共4页
Journal of Practical Dermatology
基金
新疆维吾尔自治区重点研发计划项目(2021B03001)
